SEPN SEPTERNA INC

Septerna to Participate in Upcoming Investor Conferences

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September:

Cantor Global Healthcare Conference 2025

Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET

2025 Wells Fargo Healthcare Conference

Fireside chat on Friday, September 5, 2025, at 8:45 a.m. ET

Live webcasts of the presentations will be available in the investors section of the company’s website at Replays will be archived for at least 30 days following each event.

About Septerna

Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit .

Investor Contact:

Renee Leck, THRUST

Media Contact:

Carly Scaduto



EN
27/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEPTERNA INC

 PRESS RELEASE

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna to Present at TD Cowen 46th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston. A live webcast of the presentation will be available in the investors section of the company’s website at ...

 PRESS RELEASE

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company’s Board of Directors granted an inducement award to Mark A. Wilson, Septerna’s Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company’s 2026 Inducement Plan. The award was granted as an inducem...

 PRESS RELEASE

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for th...

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from its Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, taking place February 27-March 2, 2026, in Philadelphia. SEP-631 is a ...

 PRESS RELEASE

Septerna Expands Leadership with Appointment of Industry Veteran Mark ...

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. ...

 PRESS RELEASE

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco. A live webcast of the presentation will be available in the investors section of the co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch